Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Intrapleural Infusion for Malignant Pleural Effusion in EGFR Lung Cancer
ChiCTR2300074258Phase 4Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in bronchial carcinoma and malignant pleural effusion (MPE), sponsored by Renmin Hospital of Wuhan University. Primary endpoints: progression-free survival and overall survival. Started Aug 2023; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
bronchial carcinomamalignant pleural effusion (MPE)
Beyond the preview
Go deeper on ChiCTR2300074258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074258.